The clinical evidence has demonstrated that MIF levels are higher in the cerebrospinal fluid (CSF) of the patients with progressive MS compared to those with non-progressive forms; further, primary progressive MS patients exhibit increased levels of serum TNF-α [86]. Here, TNF is linked to myeloid sarcoma.